Cancer screening in sexual and gender minority populations: A systematic review and meta-analysis.
Atulya Aman Khosla(Baptist Hospital of Miami), Ulka N. Vaishampayan(University of Michigan), Venkataraghavan Ramamoorthy(Baptist Health South Florida), Ishmael Jaiyesimi(Beaumont Hospital, Royal Oak), Rohit Singh(University of Vermont Medical Center), Nitya Batra(Jacksonville College), Karan Jatwani(Roswell Park Comprehensive Cancer Center), Anshul Saxena(Baptist Hospital of Miami), Muni Rubens(Florida International University)
Cited by 1
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
|New England Journal of Medicine|2013|568
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
|Journal of Clinical Oncology|2019|147
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|125
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|116